Laboratory Investigations for Bleeding Disorders

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 7, 2012, Pages 742-752

  Hayward, Catherinep M ^a   Moffat, Karena ^a,b   Liu, Yang ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

bleeding disorders; factor deficiencies; fibrinogen; laboratory testing

Indexed keywords

FIBRINOGEN;

ARTICLE; BLEEDING DISORDER; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIGHT TRANSMISSION PLATELET AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT REFERRAL; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; THROMBIN TIME; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; BLOOD PLATELET DISORDERS; HUMANS; PARTIAL THROMBOPLASTIN TIME;

EID: 84872103860     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1326780     Document Type: Article

References (59)

1. Watson H. G., Greaves M. Can we predict bleeding? Semin Thromb Hemost: 2008; 34 1 97 103
2. Chee Y. L., Greaves M. Role of coagulation testing in predicting bleeding risk. Hematol J: 2003; 4 6 373 378
3. Hayward C. P., Moffat K. A., Plumhoff E., Van Cott E. M. Approaches to investigating common bleeding disorders: an evaluation of North American coagulation laboratory practices. Am J Hematol: 2012; 87 01 S45 S50
4. Hayward C. P. Diagnosis and management of mild bleeding disorders. Hematology (Am Soc Hematol Educ Program): 2005; 2005 1 423 428
5. Puetz J. Thrombin time and fibrinogen as initial screening tests for people with inherited bleeding disorders. Haemophilia: 2010; 16 4 700 701
6. Verhovsek M., Moffat K. A., Hayward C. P. Laboratory testing for fibrinogen abnormalities. Am J Hematol: 2008; 83 12 928 931
7. Dzik W. H. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep: 2004; 3 5 324 330
8. Hayward C. P., Harrison P., Cattaneo M., Ortel T. L., Rao A. K.; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost: 2006; 4 2 312 319
9. Harrison P., Mackie I., Mumford A., et al.; British Committee for Standards in Haematology Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol: 2011; 155 1 30 44
10. Hayward C. P., Pai M., Liu Y., et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost: 2009; 7 4 676 684
11. Hayward C. P., Moffat K. A., Raby A., et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol: 2010; 134 6 955 963
12. Hayward C. P. Diagnostic evaluation of platelet function disorders. Blood Rev: 2011; 25 4 169 173
13. Morris W. H., Kumar A. What is the significance of an isolated elevated activated partial thromboplastin time in the preoperative setting? Cleve Clin J Med: 2007; 74 01 S13 S15
14. Carling M. S., Jeppsson A., Wessberg P., Henriksson A., Baghaei F., Brisby H. Preoperative fibrinogen plasma concentration is associated with perioperative bleeding and transfusion requirements in scoliosis surgery. Spine: 2011; 36 7 549 555
15. Abbasi S., Khan F. A. Effect of pre-operative coagulation testing on intra-operative transfusion requirements in surgical patients. J Coll Physicians Surg Pak: 2005; 15 6 319 322
16. Ng K. F., Lai K. W., Tsang S. F. Value of preoperative coagulation tests: reappraisal of major noncardiac surgery. World J Surg: 2002; 26 5 515 520
17. Schramm B., Leslie K., Myles P. S., Hogan C. J. Coagulation studies in preoperative neurosurgical patients. Anaesth Intensive Care: 2001; 29 4 388 392
18. Howells R. C. II, Wax M. K., Ramadan H. H. Value of preoperative prothrombin time/partial thromboplastin time as a predictor of postoperative hemorrhage in pediatric patients undergoing tonsillectomy. Otolaryngol Head Neck Surg: 1997; 117 6 628 632
19. Zwack G. C., Derkay C. S. The utility of preoperative hemostatic assessment in adenotonsillectomy. Int J Pediatr Otorhinolaryngol: 1997; 39 1 67 76
20. Houry S., Georgeac C., Hay J. M., Fingerhut A., Boudet M. J.; The French Associations for Surgical Research. A prospective multicenter evaluation of preoperative hemostatic screening tests. Am J Surg: 1995; 170 1 19 23
21. Borhany M., Pahore Z., Ul Qadr Z., et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis: 2010; 5 23
22. Macpherson C. R., Jacobs P., Dent D. M. Abnormal peri-operative haemorrhage in asymptomatic patients is not predicted by laboratory testing. S Afr Med J: 1993; 83 2 106 108
23. Burk C. D., Miller L., Handler S. D., Cohen A. R. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics: 1992; 89 4 Pt 2 691 695
24. Schmidt J. L., Yaremchuk K. L., Mickelson S. A. Abnormal coagulation profiles in tonsillectomy and adenoidectomy patients. Henry Ford Hosp Med J: 1990; 38 1 33 35
25. Bushick J. B., Eisenberg J. M., Kinman J., Cebul R. D., Schwartz J. S. Pursuit of abnormal coagulation screening tests generates modest hidden preoperative costs. J Gen Intern Med: 1989; 4 6 493 497
26. Manning S. C., Beste D., McBride T., Goldberg A. An assessment of preoperative coagulation screening for tonsillectomy and adenoidectomy. Int J Pediatr Otorhinolaryngol: 1987; 13 3 237 244
27. Suchman A. L., Mushlin A. I. How well does the activated partial thromboplastin time predict postoperative hemorrhage? JAMA: 1986; 256 6 750 753
28. Close H. L., Kryzer T. C., Nowlin J. H., Alving B. M. Hemostatic assessment of patients before tonsillectomy: a prospective study. Otolaryngol Head Neck Surg: 1994; 111 6 733 738
29. Suchman A. L., Griner P. F. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med: 1986; 104 6 810 816
30. Watel A., Jude B., Caron C., Vandeputte H., Gaeremynck E., Cosson A. Successes and failures of the activated partial thromboplastin time in the preoperative evaluation. Ann Fr Anesth Reanim: 1986; 5 1 35 39
31. Eisenberg J. M., Clarke J. R., Sussman S. A. Prothrombin and partial thromboplastin times as preoperative screening tests. Arch Surg: 1982; 117 1 48 51
32. Peterson P., Hayes T. E., Arkin C. F., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg: 1998; 133 2 134 139
33. Biron C., Mahieu B., Rochette A., et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med: 1999; 134 6 605 609
34. Xu J., Yu Z., Zhang L., Ruan C., Yang R. Diagnosis and management of von Willebrand disease in China. Semin Thromb Hemost: 2011; 37 5 607 614
35. Woods A. I., Sánchez-Luceros A., Meschengieser S. S., Kempfer A. C., Blanco A. N., Lazzari M. A. Diagnosis and management of von Willebrand disease in a single institution of Argentina. Semin Thromb Hemost: 2011; 37 5 568 575
36. Favaloro E. J., Bonar R., Favaloro J., Koutts J. Diagnosis and management of von Willebrand disease in Australia. Semin Thromb Hemost: 2011; 37 5 542 554
37. Flood V. H., Gill J. C., Friedman K. D., Bellissimo D. B., Haberichter S. L., Montgomery R. R. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost: 2011; 37 5 528 534
38. Federici A. B., Bucciarelli P., Castaman G., et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost: 2011; 37 5 511 521
39. Lassila R., Holme P. A., Landorph A., Petrini P., Onundarson P. T., Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. Semin Thromb Hemost: 2011; 37 5 495 502
40. Keeney S., Collins P., Cumming A., Goodeve A., Pasi J. Diagnosis and management of von Willebrand disease in the United Kingdom. Semin Thromb Hemost: 2011; 37 5 488 494
41. de Wee E. M., Leebeek F. W., Eikenboom J. C. Diagnosis and management of von Willebrand disease in The Netherlands. Semin Thromb Hemost: 2011; 37 5 480 487
42. Favaloro E. J. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost: 2011; 37 5 440 455
43. Favaloro E. J. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis: 2011; 22 7 553 564
44. Dutt T., Burns S., Mackett N., Benfield C., Lwin R., Keenan R. Application of UKHCDO 2004 guidelines in type 1 von Willebrand Disease-a single centre paediatric experience of the implications of altered or removed diagnosis. Haemophilia: 2011; 17 3 522 526
45. Nichols W. L., Hultin M. B., James A. H., et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia: 2008; 14 2 171 232
46. Castilloux J. F., Moffat K. A., Liu Y., Seecharan J., Pai M., Hayward C. P. A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples? Thromb Haemost: 2011; 106 4 675 682
47. Pai M., Wang G., Moffat K. A., et al. Diagnostic usefulness of a lumi-aggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. Am J Clin Pathol: 2011; 136 3 350 358
48. Quiroga T., Goycoolea M., Matus V., et al. Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays. Br J Haematol: 2009; 147 5 729 736
49. Mezzano D., Quiroga T., Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost: 2009; 35 2 242 254
50. Remaley A. T., Kennedy J. M., Laposata M. Evaluation of the clinical utility of platelet aggregation studies. Am J Hematol: 1989; 31 3 188 193
51. Nair S. C., Dargaud Y., Chitlur M., Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia: 2010; 16 05 85 92
52. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol: 1957; 17 4 237 246
53. Hayward C. P., Moffat K. A., Pai M., et al. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost: 2008; 100 1 134 145
54. Zeller J. A., Schlesinger S., Runge U., Kessler C. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia: 1999; 40 2 186 189
55. Hauser E., Seidl R., Freilinger M., Male C., Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev: 1996; 18 2 105 109
56. Lawrie A. SKS, Kitchen S., Purdy G., Mackie I. J., Preston F. E., Machin S. J. Assessment of actin FS and actin FSL sensitivity to specific clotting factor deficiencies. Clin Lab Haematol: 1998; 20 3 179 186
57. Peyvandi F., Palla R., Menegatti M., et al. European Network of Rare Bleeding Disorders Group Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost: 2012; 10 4 615 621
58. Peyvandi F., Palla R., Menegatti M., Mannucci P. M. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost: 2009; 35 4 349 355
59. Acharya S. S., Coughlin A., Dimichele D. M.; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost: 2004; 2 2 248 256